The phase 2 trials of the drug, which were sponsored by the nonprofit group Multidisciplinary Association for Psychedelic Studies, focused on treating patients who had struggled with PTSD symptoms for an average of 17 years, according to The New York Times. After one trial, two-thirds of the patients' symptoms improved so much, they could no longer be diagnosed as having PTSD.
If the drug gets approved, it could be available as early as 2021, but it would have to be administered to patients under the watchful eye of a trained psychotherapist, and as part of a more comprehensive treatment program. This hopefully will make it harder for recreational users to get their hands on the drug, since some experts worry MDMA abuse could end up like the current opioid addiction epidemic. And no, most DJs don't have psychiatric training.
Still, if the positive trial results are any indication, those suffering from severe PTSD, especially combat veterans, victims of abuse, and first responders, could finally find the relief they so desperately need.